Biocartis Group NV announced that they have entered into a new post-commercial collaboration program with Lilly. This program will explore the advantages of adding the Biocartis IdyllaTM Platform to a molecular diagnostics workflow in global clinical labs via a study in hospitals across Spain. The focus will be to understand how the Idylla?

Platform can contribute to a more expeditious and comprehensive approach to identify targetable alterations when compared to various current clinical workflows for NSCLC patients. The intention of the Lilly-sponsored study in Spain is that the results will guide and improve US community-based diagnostic workflows by the introduction of the Idylla platform. The outcome data is expected to be presented in the fall of 2024.